Data Integrity in Pharma: Connecting ALCOA+, 21 CFR and QMS

Introduction

In pharmaceutical operations, every quality decision depends on the reliability of the data behind it.

A batch release, a deviation investigation, a CAPA decision, a quality inspection, or an electronic approval can only be supported when the records are precise, traceable, whole, and accessible when required.

This is why data integrity has become a core concern for regulated companies. It is not simply about storing information. It is about ensuring that information can be trusted throughout its lifecycle, from creation and review to approval, retention, and retrieval.

Three concepts are especially relevant in this discussion: ALCOA+, 21 CFR Part 11, and the Quality Management System. ALCOA+ defines what trustworthy data should look like. 21 CFR Part 11 provides a regulatory framework for electronic records and electronic signatures in FDA-regulated environments. The QMS organizes the processes, responsibilities, and controls that help apply these expectations in daily quality operations.

For pharmaceutical companies moving away from paper records, spreadsheets, and disconnected tools, understanding how these three elements work together is essential.

What Is ALCOA+ in Pharma Data Integrity?

ALCOA+ is a widely used framework for assessing data integrity in GxP environments. It stands for data that is Attributable, Legible, Contemporaneous, Original, and Accurate. The "+" adds four additional expectations: Complete, Consistent, Enduring, and Available. Many practitioners simply say ALCOA when referring to the core elements, with the "+" denoting the extended expectations.

The WHO (World Health Organization) highlights the importance of data governance to ensure the reliability of data and records in GxP activities and regulatory submissions, and refers to ALCOA+ principles in this context.

In practical terms, ALCOA+ asks a direct question: can this data be trusted ?

A quality record should make it possible to understand who created the data, when it was created, what original information it came from, whether it was changed, why it was changed, and whether it can still be retrieved during an audit or inspection.

This makes ALCOA+ more than a documentation acronym. It is a practical way to evaluate whether quality data can support a defensible business, regulatory, or product decision.

What Is 21 CFR Part 11?

21 CFR Part 11 applies to certain electronic records and electronic signatures used in FDA-regulated contexts. FDA guidance explains that Part 11 applies to electronic records that are created, modified, maintained, archived, retrieved, or transmitted under FDA record requirements, as well as electronic records submitted to the FDA under applicable laws.

In simpler terms, Part 11 helps define when electronic records and electronic signatures can be considered trustworthy, reliable, and generally equivalent to paper records and handwritten signatures.

For closed systems, 21 CFR §11.10 describes controls such as system validation, accurate and complete record copies, record protection, limited system access, secure time-stamped audit trails, operational checks, and authority checks.

These controls matter because many pharmaceutical quality processes are now digital: electronic approvals, deviation workflows, CAPA follow-up, batch records, document control, quality inspections, and training records.

How ALCOA+ and Part 11 Work Together

ALCOA+ and 21 CFR Part 11 are not the same thing, but they are closely connected.

ALCOA+ focuses on the quality and trustworthiness of the data.

Part 11 focuses on the controls around electronic records and electronic signatures.

A useful way to understand the relationship is this:

How ALCOA+ Principles Connect to 21 CFR Part 11 and QMS Requirements

The connection is clear: ALCOA+ defines the data integrity expectation, while Part 11 supports the electronic controls needed to protect that data.

Where the QMS Fits In

The QMS is where data integrity becomes operational.

A pharmaceutical QMS defines how quality processes are managed, documented, reviewed, and improved. It may include deviations, CAPA, change control, audits, training, document control, supplier management, quality inspections, and batch-related decisions.

Without a structured QMS, ALCOA+ remains a principle rather than a daily practice. Without controlled electronic systems, Part 11 remains a regulatory requirement rather than an operational safeguard. Together, QMS processes and digital controls help transform data integrity expectations into usable evidence.

For example, a deviation workflow should not only capture the event. It should define who can open the deviation, who investigates it, how the root cause is documented, how CAPA is assigned, how approvals are captured, and how the final record remains available for future review.

That is the practical bridge between compliance, data integrity, and daily quality operations.

Why Disconnected Systems Create Data Integrity Risks

Many pharmaceutical companies still manage quality information across multiple tools: spreadsheets for deviations, emails for approvals, ERP for inventory, separate QMS tools for CAPA, and shared folders for documentation.

At first, this approach may seem manageable. Over time, however, disconnected systems create gaps.

A batch release decision may depend on QC results, lot status, warehouse movements, production records, deviation status, and QA approval. If these records live in different systems, it becomes harder to prove that the evidence is complete, consistent, original, attributable, and available.

The issue is not always that records are missing. Often, the issue is that the information is difficult to connect.

This is where companies should ask practical questions:

Can we trace a quality decision back to the original data?

Can we see who approved what, and when?

Can we retrieve complete records quickly during an audit?

Can we prove that only authorized users made critical changes?

Can quality status directly control operational actions?

If the answer is unclear, the organization may be exposed to data integrity risk. FDA guidance on data integrity and CGMP emphasizes that firms should implement meaningful and effective strategies to manage data integrity risks based on their process understanding and knowledge of their technologies and business models.

From Compliance Requirement to Quality Evidence

Audit trails, electronic signatures, validation, and access controls should not be treated as technical checkboxes. In pharmaceutical operations, they are part of the evidence that supports quality decisions.

An audit trail helps show what changed, when it changed, and who changed it. An electronic signature formalizes accountability. Access control helps ensure that only authorized users can perform critical actions. Validation provides confidence that the system performs as intended.

When these controls are connected to QMS workflows, they become more powerful. They help quality teams demonstrate not only that a procedure exists, but that it was followed, documented, reviewed, and preserved.

That is the real value of connecting ALCOA+, Part 11, and QMS: it turns compliance expectations into usable, reviewable, and audit-ready evidence.

Why ERP-QMS Integration Matters

In pharma, quality decisions often affect operations directly. A material may need to remain in quarantine. A lot may need to be blocked. A batch may not be released until a deviation is reviewed. A supplier issue may affect purchasing decisions. A CAPA may require process changes.

If the QMS is disconnected from the ERP, quality decisions may not translate clearly into operational control.

This is why integration matters. Quality information should not live far away from the operational decisions it controls. By connecting QMS workflows with ERP processes, pharmaceutical companies can improve visibility, traceability, and consistency across quality, inventory, production, and documentation.

Conclusion

ALCOA+, 21 CFR Part 11, and QMS are closely connected. ALCOA defines the core elements of what trustworthy data should be, while ALCOA+ adds extended expectations. Part 11 outlines controls for electronic records and electronic signatures in FDA-regulated contexts. The QMS organizes the workflows, responsibilities, and procedures that apply these expectations every day.

For pharmaceutical companies, data integrity is not only a compliance topic. It is a system design challenge. The more fragmented the systems, the harder it becomes to prove that records are controlled, traceable, complete, and audit-ready.

Ready to connect data integrity, QMS, and pharma operations?

VFFICE helps regulated companies bring quality workflows, traceability, documentation, approvals, and operational controls closer together within Microsoft Dynamics 365 Business Central.

For pharmaceutical and life sciences organizations, VFFICE Boost Pharma supports pharma-focused workflows such as traceability, documentation, quality controls, and regulated operational processes.

For companies looking to strengthen their quality management approach more broadly, VFFICE Quality Management provides a dedicated option to support QMS-related processes within Business Central.

If your organization is looking to move from disconnected quality records to more connected, controlled, and audit-ready processes, contact VFFICE to explore which solution best fits your QMS and ERP strategy.

Book a meeting with our team

🔎Discover how VFFICE Boost Pharma can help make Business Central more pharma-ready.

Rim El kassaby ( pharma consultant )

Msc. Clinical Pharmacology